Cybin (HELP) Stock Price, News & Analysis
Company Description
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing proprietary neuroactive compounds for mental health conditions. The company describes these compounds as novel serotonergic agonists, or NSAs: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. Its listed securities trade under the symbol HELP on Nasdaq and Cboe Canada.
The company's development work is centered on depression, anxiety, and other mental health conditions. Its lead disclosed program, HLP003, is a proprietary NSA in clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004 is a proprietary NSA in clinical development for generalized anxiety disorder. Helus Pharma also reports a broader research portfolio of investigational NSAs.
Helus Pharma's business model is organized around pharmaceutical research and clinical development rather than commercial product sales. Its operating activities include advancing investigational compounds through clinical programs, engaging with regulators, building medical and scientific capabilities, and supporting clinical research participation for its mental health pipeline. The company has described operations in Canada, the United States, the United Kingdom, and Ireland.
As a public clinical-stage issuer, Helus Pharma's corporate record includes pipeline updates, clinical and regulatory disclosures, governance changes, capital-structure matters, and operating and financial results. The company was formerly known to public markets as Cybin Inc. while using Helus Pharma as its commercial operating name.
Stock Performance
Cybin (HELP) stock last traded at $7.11, down 3.18% from the previous close. Over the past 12 months, the stock has lost 8.0%. At a market capitalization of $449.4M, HELP is classified as a small-cap stock with approximately 62.0M shares outstanding.
HELP Rankings
Latest News
Cybin has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, offering, clinical trial, partnership, management. View all HELP news →
SEC Filings
Cybin has filed 5 recent SEC filings, including 2 Form 6-K, 2 Form D, 1 Form 40-F. The most recent filing was submitted on July 16, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all HELP SEC filings →
Financial Highlights
Upcoming Events
Phase 3 HLP003 topline
Topline Phase 3 data
APPROACH topline readout
HLP003 Phase 3 readout
HLP003 Phase 3 topline
Topline Phase 3 data HLP003
Cybin has 6 upcoming scheduled events. The next event, "Phase 3 HLP003 topline", is scheduled for October 1, 2026 (in 71 days). Investors can track these dates to stay informed about potential catalysts that may affect the HELP stock price.
Short Interest History
Short interest in Cybin (HELP) currently stands at 3.0 million shares, down 3.7% from the previous reporting period, representing 6.2% of the float.
Days to Cover History
Days to cover for Cybin (HELP) currently stands at 1.6 days, down 69.7% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 70% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.1 to 9.8 days.
HELP Company Profile & Sector Positioning
Cybin (HELP) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ. In monthly performance, the stock ranks #190 among all tracked companies.